Abstract Cerebral cavernous malformations (CCM) are vascular lesions associated with loss-of-function mutations in one of the three genes encoding KRIT1 (CCM1), CCM2, and PDCD10. Recent understanding of the molecular mechanisms that lead to CCM development is limited. The role of microRNAs (miRNAs) has been demonstrated in vascular pathologies resulting in loss of tight junction proteins, increased vascular permeability and endothelial cell dysfunction. Since the relevance of miRNAs in CCM pathophysiology has not been elucidated, the primary aim of the study was to identify the miRNA-mRNA expression network associated with CCM. Using small RNA sequencing, we identified a total of 764 matured miRNAs expressed in CCM patients compared to the healthy brains. The expression of the selected miRNAs was validated by qRT-PCR, and the results were found to be consistent with the sequencing data. Upon application of additional statistical stringency, five miRNAs (let7b-5p, miR-361-5p, miR-370-3p, miR-181a-2-3p, and miR-95-3p) were prioritized to be top CCM-relevant miRNAs.
Introduction
Cerebral cavernous malformations (CCM) are neurovascular lesions affecting approximately 0.5% of the general population (Fisher et al. 2013; Kar et al. 2016) . The lesions comprise dilated capillary vessels without intervening brain parenchyma, and symptoms include severe headaches, focal neurological deficits, and seizures (Bertalanffy et al. 1992; Gingras et al. 2012; Samii et al. 2001; Schulz et al. 2015) (Fig. 1) . CCM may occur either as sporadic or as familial forms. The familial cases consist of autosomal-dominantly inherited forms with incomplete clinical penetrance Hwang and Pallas 2014; Kar et al. 2015) . A majority of inherited forms of CCM follow a Bsecond hit^or a Knudsonian mutation, where loss of one allele due to a germline mutation in an affected cell (first hit) is succeeded by a somatic mutation in the other (second hit) (Akers et al. 2009 ). So far, three types of mutations have been identified in the CCM-causing genes, KRIT1 (CCM1), CCM2 (OSM or Electronic supplementary material The online version of this article (doi:10.1007/s12031-017-0880-6) contains supplementary material, which is available to authorized users. malcavernin), and PDCD10 (CCM3), and the products of these genes have been predicted to be involved in a common functional pathway (Draheim et al. 2014) . A recent hypothesis regarding the existence of a fourth unidentified CCM gene was also proposed to explain the low frequency of mutation identified in families within PDCD10 (10%) at the CCM3 locus (Riant et al. 2010) . Despite recent advances in understanding the structure and function of these proteins, much remains to be known how the loss of such proteins leads to CCM pathogenesis.
MicroRNAs (miRNAs) represent a class of short, noncoding RNAs, about 20~22 nucleotides in length that posttranscriptionally regulate gene expression. During its biogenesis, the mature strand incorporates into the RNA-induced silencing complex (RISC) and results in translational repression by binding to the complementary sequences of the messenger RNAs (Kala et al. 2013) . MiRNAs have been implicated in diverse biological activities including tumorigenesis (Dong et al. 2010) , hematopoiesis (Chen et al. 2004) , epigenetics (Dong et al. 2010) , and angiogenesis (Suarez and Sessa 2009; Yin et al. 2015) . MiRNAs that are involved in the process of angiogenesis are classified as BangiomiRs,^and a plethora of angiomiRs have been recently identified across various animal models, including mice, zebrafish, and humans . For instance, miR-126 is highly enriched in the endothelial cells and has an essential role in the blood vessel formation and integrity (Lopez-Ramirez et al. 2016; Wang et al. 2008) . Another potent angiomiR, miR-210, is a well-known mediator of angiogenesis and has been found to be significantly up-regulated following cerebral ischemia in rats (Lou et al. 2012) . Although there are studies reporting the role of miRNAs in angiogenesis Seok et al. 2014; Suarez and Sessa 2009; Wang et al. 2013) , in the pathogenesis of ischemic brain injury (Li et al. 2016; Liu et al. 2013; Tan et al. 2009; Yin et al. 2010) , and in cerebral arteriovenous malformation (AVM) (Ferreira et al. 2014) , their relevance to CCM biology has been so far not reported.
Using genome-wide miRNA sequencing, we aimed to identify the miRNA expression profile in CCM patients compared with healthy brains. Applying the highest level of statistical stringency resulted in candidate miRNAs being significantly downregulated in CCM. After shortlisting the prioritized miRNAs, we sought to identify their target genes associated with CCM. Our search represented notable enrichment of CCM-relevant genes. Identification of genes targeted by these candidate miRNAs might help to understand their mechanism of regulation during CCM development and might therefore aid in developing future therapeutic targets.
Methods

Ethics Statement
The study was performed in accordance with the guidelines and with permission by the Ethical Committee of the Hannover Medical School, Germany (Approval Number 6960).
Patient Sample Collection
Brainstem biopsies obtained from three patients (Cav1, Cav2, and Cav3) operated due to cavernous malformations were snap frozen in liquid nitrogen. The samples were stored temporarily at −80°C until total RNA extraction. CCM diagnosis was based on the MRI and histopathological criteria as described previously (Bertalanffy et al. 2002) . Each patient had at least one or more clinical presentations manifested by seizures, hemorrhages, and focal neurological deficits (Table 1) . Additionally, three commercially available Human Brain Reference Total RNAs (Amsbio) (Con1, Con2, and Con3) pooled from a healthy adult brain were used as corresponding controls.
RNA Isolation and Integrity
Tissue biopsies were stored in at least 10 volumes of RNAlater-ICE (AM7030; Ambion) at −80°C prior to RNA Fig. 1 Representative MRI image of an intra-axial brainstem cavernoma. Axial T2-weighted MRI scan of a 52-year-old female with a large cavernoma located in the upper Pons (yellow arrow). The patient suffered from severe dizziness, numbness on the left side of the face, and hypoesthesia on the left body side. Images and clinical data were kindly provided by Prof. Helmut Bertalanffy (Vascular Neurosurgery, INI, Hannover) extraction. The tissue was lysed using ceramic beads (Precellys system, CK14L; Peqlab) in 600 μl of lysis buffer from a mirVana miRNA Isolation Kit (AM1560; Ambion). Homogenization was performed using a Precellys 24 homogenizer (Peqlab) with four pulses of 5 s at 6000 rpm. Total RNA was extracted with the mirVana Kit according to the recommended protocol variant for total RNA including small species. RNA was finally eluted with 100 μl of elution solution preheated to 95°C. Eluted RNA (87.5 μl) was subjected to a DNase I treatment in solution for 10 min at RT by adding 10 μl of buffer RDD and 2.5 μl of DNase I, both taken from a RNeasy Micro Kit (74004; Qiagen). After DNase I treatment, 10 μl of 5 M NaCl and 152 μl of 100% ethanol were added, and both were thoroughly mixed and loaded onto an RNeasy column for final purification according to the standard RNeasy procedure, except that buffer RW1 was diluted 1:3 with 100% ethanol prior to usage (in order to enable binding of even small RNA species to the silica matrix). Total RNA was finally eluted with 14 μl of RNase-free water. RNA was quantified, and purity was determined with the NanoDrop ND-1000 spectrophotometer (Peqlab). RNA integrity was determined with an Agilent Bioanalyzer 2100 using the RNA 6000 Nano Assay (5067-1511; Agilent Technologies). RNA integrity numbers (RINs) ranged from 7.7 to 8.3 for the RNA samples purified from CCM tissues and 8 to 9 for the three normal human brain tissues.
Library Preparation and Sequencing
The RNA sequencing library was generated from 50 to 100 ng total RNA using TruSeq® Small RNA Library Prep Kits v2 (Illumina) according to manufacturer's protocols. The libraries were sequenced on Illumina HiSeq2500 using TruSeq SBS Kit v3-HS (50 cycles, single-ended run) with an average of 10 × 10 6 reads per RNA sample.
Bioinformatics and Data Analysis
Raw data (FASTQ files) were applied to an Oasis 1.0 sRNA Detection pipeline (Capece et al. 2015 . Differential expression of small RNA was determined by DESeq2 (Love et al. 2014 ).
Differential Expression
Following alignment, the read counts of each small RNA element were converted to Breads per million^(RPM) using the following formula: normalized expression = reads assigned to a unique sequence in a sample / total number of reads identified by all sequences in that sample × 1,000,000 (Motameny et al. 2010 ). The matured miRNAs were then filtered from other small non-coding RNAs (novelmiRNAs, snoRNAs, piRNAs, and rRNAs). This yielded a total of 764 matured miRNA sequences. Next, we applied an arbitrary filter of RPM values ≥30 in at least two out of six tested samples. This came down to 327 differentially expressed miRNAs in CCM compared to the control samples. The differential expression of the individual miRNAs was calculated based on the degree to which the RPM values were up-or downregulated in CCM with respect to the control samples. This was statistically evaluated as follows: For each miRNAs in each of the Cavernoma pools (Cav 1, Cav 2, and Cav 3), we calculated differential regulation with respect to each of the Control (Con 1, Con 2, and Con 3) pools (Cav 1/ Con 1), (Cav1/Con 2), (Cav 1/Con 3), (Cav 2/Con 1), (Cav 2/ Con 2), (Cav 2/Con 3) and (Cav 3/Con 1), (Cav 3/Con 2), and (Cav 3/Con 3). The result was nine estimates of differentially regulated CCM with a corresponding mean ± standard error of the mean (SEM). The same was done for calculating the 
qRT-PCR Validation of miRNAs
To validate the sequencing data, we randomly selected three miRNAs downregulated in CCM tissue samples with the highest statistical stringency. Forty nanograms of total RNA was reverse transcribed with miRNA-specific RT primers using the TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems, no. 4366597) following the manufacturer's protocol. Using miRNA-specific primers and TaqMan® Universal Master Mix II-no UNG (Applied Biosystems, no. 4440040), the cDNA template was amplified with the help of StepOnePlus™ Real-Time PCR (Applied Biosystems, Germany). The assay numbers to validate miRNAs are as follows: hsa-let-7b-5p (002619), hsa-miR181a-2-3p (002317), and hsa-miR-95-3p (000433). Expression levels of the target miRNAs were normalized to that of RNU6B (assay number 001093), and the fold change was determined by 2 −ΔΔCt
. All reactions were run in triplicate.
Prediction of Putative and Validated Gene Targets
Target prediction for the five downregulated miRNAs was determined in silico using the miRWalk 2.0 algorithm. Briefly, the selected miRNAs were uploaded on the BPredicted and Validated Target Module^of miRWalk 2.0 search option and the subsequent list of putative and experimentally validated targets relative to each prioritized miRNAs was obtained. These were further scanned and analyzed for Gene Ontology Molecular Function (GOMF) enrichment terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway classification. Network analysis for miRNA-messenger RNA (mRNA) putative target interaction was carried out using Cytoscape 3.3.0.
Statistical Analysis
All data are expressed as mean ± standard error of the mean (SEM). The one-way ANOVA test was used to calculate the significance of differential expression level for each miRNA between CCM and normal brain. Heatmaps for the 52 significantly differentially regulated miRNAs were plotted using freely available online software, matrix2png (Pavlidis and Noble 2003) . For the estimation of significant miRNAs, Benjamini-Hochberg FDR correction (adjusted p values) (Benjamini and Hochberg 1995) was applied. For extra confidence, the Bonferroni multiple-comparison correction method (adjusted p values) was implemented to assess the statistically significant miRNAs. Corrected p ≤ 0.05 was considered to be statistically significant.
Results miRNA Sequencing in CCM Patients
Procurement of fresh healthy human brain tissue has always been a challenging task. Also, a major practical concern during microsurgical resection lies in delineating adjacent healthy brain tissue from the CCM lesion. On the other hand, Amsbio Human Brain Reference Total RNA pooled from healthy individuals is a robust, thoroughly characterized commercially available human tissue RNA widely used as a standard reference for studying changes in miRNA expression. Total RNA isolated from CCM patients (n = 3) and commercially available FirstChoice® Human Brain Reference RNA (n = 3) were sequenced for small RNAs. After trimming of FASTAQ files and removal of the adapter sequences, 16 to 23 million read sequences belonging to each sample were mapped to the human genome, with a total of 118.9 million reads. The minimum and maximum read length was between 15 and 32 nucleotide sequences, and the average read lengths for six libraries were Con 1, 21.50 bp; Con 2, 21.57 bp; Con 3, 21.65 bp; Cav1, 21.59 bp; Cav2, 21.82 bp; and Cav3, 21.82 bp, respectively. miRBase-v20 recognizes a total of 2555 mature human miRNA sequences. Of these annotated mature miRNAs, 764 were identified to be expressed in the six libraries sequenced. The abundance of each small RNA was normalized using Breads per million (RPM)^in each small RNA library (see BMethods^) which ranged from several hundreds to millions. For example, in the Cav1 library, 55.23% miRNAs were low expressed (<10 RPM), 43.45% were moderately expressed (10-10,000 RPM), and only 1.32% of them were abundantly expressed (>10,000 RPM) (Fig. 2) . In order to identify the miRNAs that were stably expressed across biological samples, we applied an arbitrary filter having RPM values ≥30 in at least two out of six tested samples as previously described (Bali et al. 2013 ). Applying such filter resulted in 327 miRNAs with stable expression and abundance across CCM tissues. A pairwise comparison of the 327 expressed miRNAs between CCM and healthy brain is shown in the volcano plot (Fig. 3) .
Differential Regulation of miRNAs in CCM
Following identifying a set of stably expressed miRNAs in healthy and CCM tissue samples, we investigated the magnitude and significance of changes in miRNA expression between the two groups. For this, we first calculated the fold change in the expression of each of 327 miRNAs in the CCM samples as compared to healthy brain samples (as explained in the BMethods^section). Applying a statistical p value cutoff of 0.05 revealed that expression of 162 miRNAs was significantly different in CCM tissue samples. In the next steps, we calculated the adjusted p value (adjP) by applying Benjamini-Hochberg FDR correction for highthroughput experiments and identified that 52 miRNAs were regulated in CCM with high statistical confidence in comparison to healthy brain samples. The results of these 52 significantly regulated miRNAs are summarized as additional file 1: Table S1 . Among them, 10 were significantly up-regulated with miR-27a-5p having the highest fold change (79.78, padj ≤0.05) followed by miR-21-5p (67.99, padj ≤0.05), miR146b-5p (24.08, padj ≤0.05), miR-155-5p (19.88, padj ≤0.05), miR-210-3p (15.7, padj ≤0.05), miR-214-3p (11.02, padj ≤0.05), miR-493-3p (9.04, padj ≤0.05), miR-34a-5p (8.95, padj ≤0.05), miR-301b (6.95, padj ≤0.05), and miR-22-5p (3.69, padj ≤0.05), respectively. In addition to the upregulated miRNAs, 42 miRNAs were downregulated in CCM tissues (p ≤ 0.05) with miR-128-3p having the lowest fold change (0.007, padj ≤ 0.05) (Fig. 4) .
In the next steps, we set out to identify most biologically significant miRNAs from the above identified 52 CCMrelevant miRNAs. For this, we applied increasing levels of statistical stringency (Bali et al. 2014) for FDR correction. Executing Bonferroni-step down or Bonferroni FDR consistently identified five miRNAs (miR-95-3p, miR-370-3p, let7b-5p, miR-181a-2-3p, and miR-361-5p) to be significantly downregulated in CCM with the highest statistical stringency. This ensured extra confidence in terms of biological stability across the libraries. miR-95-3p had the lowest fold change (0.09, padj ≤0.05) followed by miR-370-3p (0.12, padj ≤0.05), let-7b-5p (0.17, padj ≤0.05), miR-181a-2-3p (0.26, padj ≤0.05), and miR-361-5p (0.36, padj ≤0.05), respectively. A brief overview of the subsequent steps applied with increasing levels of stringency is shown in Table 2 .
Validation by qRT-PCR Assay
To further validate the miRNA expression screen with an independent qRT-PCR method, we randomly chose three differentially regulated miRNAs among 52 CCM-relevant miRNAs The y-axis represents the negative of log10 (FDR-corrected padj), and the x-axis corresponds to difference log fold change. Red and green dots indicate miRNAs significantly up-and downregulated with the highest statistical stringency. Analyzing the qRT-PCR data obtained by using specific probes for let-7b-5p, miR181a-2-3p, and miR-95-3p revealed that their expression is significantly lesser in CCM tissue samples as compared to control samples (Fig. 5 ). These observations confirm that the change in the expression of the tested miRNAs is consistent with observations from the preliminary miRNA sequencing data.
Bioinformatics Analysis of the Validated miRNAs
Putative Target Gene Prediction
After identifying and validating CCM-relevant miRNAs, we sought to understand the mechanisms of action of these miRNAs. For this, we first determined putative mRNAs for each of the five miRNAs (let-7b-5p, miR-361-5p, miR-370-3p, miR-181a-2-3p, and miR-95-3p) by employing the miRWalk 2.0 algorithm. miRWalk 2.0 provides a comprehensive list of putative and validated mRNAs for a given miRNA by combining results from multiple target prediction algorithms (Dweep et al. 2011) . To augment intersample consistency within our data, we applied seven different target prediction algorithms (miRWalk, MicroT4, miRanda, miRDB, Pictar2, PITA, and TargetScan) for the identification of putative miRNA targets. Our in silico analysis revealed multiple mRNAs for each miRNA individually screened. The total numbers of highconfidence mRNA hits generated by let-7b-5p, miR-361-5p, miR-370-3p, miR-181a-2-3p, and miR-95-3p were 726, 578, 449, 101, and 23, respectively (additional file 2: Table S2 ). The search for the CCM-relevant mRNAs targeted by the five prioritized miRNAs was done manually by visual inspection and by considering CCM-relevant knowledge about each target into account. This resulted in the identification of CCMrelevant mRNAs targeted by let-7b-5p, miR-361-5p, and miR-370-3p, while miR-181a-2-3p and miR-95-3p had none (Fig. 6) .
We then extended our study to determine and rank the miRNA-mRNA putative target interaction by generating a network using Cytoscape 3.3.0 (Shannon et al. 2003) (Fig. 6) . As shown in the interaction map, the green boxes are CCM-relevant mRNAs targeted individually by miR-361-5p, miR-370-3p, and let-7b-5p. No CCM-specific mRNAs were targeted by miR-181a-2-3p and miR-95-3p.
To characterize miRNAs in terms of molecular function and to determine the underlying biological functions, we extended our approach to define which Gene Ontology Molecular Function (GOMF) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were enriched by 
Validated Target Gene Prediction
Validated or experimentally verified target mRNA prediction for each of the five downregulated miRNAs was explored in silico using the miRWalk 2.0 algorithm (Dweep et al. 2011 ). Our analysis revealed 981 mRNA hits targeted by let-7b-5p, 93 by miR-361-5p, 4 mRNAs by miR-370-3p, and 1 mRNA each by miR-95-3p and miR-181a-2-3p. As mentioned above in the BPutative Target Gene Prediction^section, we applied a similar approach for the identification of CCM-relevant mRNAs targeted by the selected miRNAs. These resulted in mRNAs MIB1, HIF1A, PDCD10, TJP1, OCLN, HES1, MAPK1, and ENG targeted by let-7b-5p which code for mindbomb E3 ubiquitin protein ligase 1 (Sure et al. 2005) , hypoxia-inducible factor 1-alpha (Sure et al. 2005) , programmed cell death 10 (Bergametti et al. 2005; Liquori et al. 2007 ), tight junction protein1 (Jakimovski et al. 2014; Schneider et al. 2011) , occludin (Schneider et al. 2011) , Hes family bHLH transcription factor 1 (You et al. 2013) , mitogenactivated protein kinase 1 (Wustehube et al. 2010) , and endoglin (Sure et al. 2005) , respectively. Additionally, miR-361-5p targeted VEGFA (You et al. 2013 ) and EGFL7 (Renz et al. 2015) while miR-370-3p targeted NF1 (Rerat et al. 2015) mRNAs. The subsequent results are summarized in Table 3 .
Discussion
CCM in the brainstem region are rare, deep-seated lesions having a higher propensity of bleeding. If left untreated, it may even lead to death of the patient. With the advent of improved diagnostic tools and the advancement of magnetic resonance imaging (MRI), there has been a significant progress in the early clinical diagnosis of brainstem CCM (Bozinov et al. 2010) . Currently, the only therapeutic option for the treatment of deep-seated CCM is microsurgical resection. Therefore, it is necessary to identify potential biomarkers that may open up new avenues for alternative therapeutic approaches. The role of miRNAs in regulating angiogenesis and in stroke pathogenesis has been reported (Kuehbacher et al. 2008; Liu et al. 2011; Wang et al. 2008; Yin et al. 2015; Yuan et al. 2016 ); however, their relevance to brain vascular malformations, notably CCM, have not been so far elucidated. Here, we report for the first time genome-wide miRNA expression profiling in CCM patients and believe that our dataset will be valuable for future research to discern the role of miRNAs in CCM pathology. Using a comprehensive genome-wide sequencing approach, we identified a total of 764 miRNAs expressed in CCM. By implementing in-depth statistical analysis, we identified 10 up-regulated and 42 downregulated miRNAs in the CCM patients. By further applying increasingly stringent statistical methods, we identified five miRNAs, namely, let-7b-5p, miR-361-5p, miR-370-3p, miR-181a-2-3p, and miR-95-3p, significantly downregulated in CCM.
A key factor in identifying the function of miRNAs is through their putative mRNAs. With the advent of bioinformatics and multiple target prediction algorithms, it has been possible to explore the function of miRNAs and establish their biological significance in diseases. A plethora of algorithms and databases have been developed based on pairing strategies between miRNA and mRNA (Khan et al. 2015) . The current available target prediction algorithms are believed to contain a high degree of false-positive rates. Therefore, in order to circumvent false positives and increase the confidentiality and credibility of true predictions, we applied seven established target prediction algorithms using web-based miRWalk 2.0 (see BResults^) (Dweep et al. 2011) . Our search yielded few -7b-5p, miR-361-5p, miR-370-3p, miR-181a-2-3p, and miR-95-3p . A most striking finding was that each of the prioritized miRNAs is predicted to target mRNAs which were previously determined to play a let-7b-5p, miR-361-5p, miR-370-3p, miR-181a-2-3p, and miR-95-3p) were identified using webbased application software Cytoscape 3.3.0. The red solid circles represent the miRNAs, while the green boxes represent their mRNA targets. The specific interaction between the miRNAs and their target genes is shown by red lines Draheim et al. 2014; Glading et al. 2007; Goitre et al. 2010; Schulz et al. 2015; Sure et al. 2005; Wustehube et al. 2010; You et al. 2013; Zawistowski et al. 2005; Zheng et al. 2010) were identified to have binding sites for one of the three prioritized miRNAs from our screen, namely, let-7b-5p, miR-361-5p, and miR-370-3p (Fig. 6) , suggesting functional validity and relevance of the screen we performed. Another interesting finding was that several of CCMrelevant mRNAs are previously characterized to be functional targets of our three prioritized miRNAs in distinct experimental systems. In other words, miRNAs prioritized from our genome-wide screen are known to functionally target several key CCM-relevant mRNAs. For example, miR-361-5p is known to modulate the expression of VEGF, a key gene involved in CCM pathophysiology, in diseased endothelial progenitor cells (EPCs) in vitro (Wang et al. 2014) . In another recent study, let-7, known as hypoxia-responsive miRNA, is robustly induced by HIF1A in the vascular endothelial cells (Chen et al. 2013) . Despite previous studies reporting the role of miRNA-mRNA in vascular endothelial cells, their mechanism of regulation in CCM would require further study.
Another critical point of interest is the mechanisms via which miRNAs function in the context of CCM. Since all five prioritized miRNAs were downregulated in cavernoma conditions, according to an existing understanding of miRNAmediated mechanisms, they are expected to predominantly target mRNAs which accelerate the cavernoma progression. Sure et al. studied the proliferative activity of the endothelium in 56 CCM patients and showed increased expression of VEGF, MIB1, HIF1, and ENG in endothelial cells (Sure et al. 2005) . On the other hand, there are genes such as TJP1, OCLN, and HES1 which are known to be downregulated in CCM conditions (Schneider et al. 2011; You et al. 2013 ) but also have binding sites for our prioritized miRNAs, which makes it difficult to explain their function with the existing model of miRNA function. However, it has to be noted that the screen represents the whole cavernoma tissue, which includes neuronal and non-neuronal cells, and the phenotype depends on the cell type-specific expression of a given miRNA and its target gene. Therefore, it would be intriguing to determine the cell type-specific mechanism interaction between prioritized miRNAs and putative/validated targets in the context of CCM. Future studies should warrant the understanding of whether miRNA-mRNA interactions follow a classical regulatory pattern in CCM pathology. Additionally, although we concentrated on only five miRNAs with strongest statistical significance, there were also 47 other miRNAs which provide an unlimited source of substrate for future studies with respect to CCM pathology.
An additional intriguing observation was the identification of several isoforms of the same mRNA to be targeted by a single miRNA. Formation of mRNA isoforms by alternative splicing is one of the important cellular mechanisms for proteome diversity. Our results revealed that 18 different isoforms for vascular endothelial growth factor A (VEGFA) have putative binding sites for miR-361-5p. VEGF is known to play a significant role in the formation of new blood vessels and is crucial for the induction of proliferation and differentiation of endothelial cells. Aberrant regulation of VEGF-mediated signaling contributes to angiogenesis and severe brain pathologies. The role of VEGF in CCM pathology has been previously reported Sure et al. 2005; You et al. 2013) . Although the role of miR-361-5p and its target VEGFA has been previously reported in human cutaneous squamous cell carcinoma and in patients with coronary artery disease (Kanitz et al. 2012; Wang et al. 2014) , their mechanism of interaction in CCM is yet to be established. Therefore, it would be extremely interesting to study the functional regulation of VEGF isoforms with respect to miR-361-5p. Another observation was the identification of the two isoforms (rac1 and rac1b) of Ras-related C3 botulinum toxin substrate 1 (RAC1) mRNA targeted by miR-361-5p. Earlier studies have reported that CCM2 binds the mitogen-activated protein kinase (MAPK) MEKK3 and RAC1 to regulate the p38 MAPK cascade (Zawistowski et al. 2005) . Besides, isoforms of six other mRNAs have putative binding sites for three of our prioritized miRNAs. Likewise for the mRNAs validated to be targets of the prioritized miRNAs, we identified that three isoforms of the gene neuroblastoma RAS viral oncogene homolog (NRAS) are targeted by let-7b-5p. From the observations above, we hypothesize that let-7b-5p, miR-361-5p, and miR-370-3p could affect CCM pathology by modulating their mRNA isoforms generated due to alternative splicing.
Conclusion
This study provides the first evidence that there are candidate miRNAs crucial for CCM pathology. We conclude that let-7b-5p, miR-361-5p, and miR-370-3p may be of biological and functional relevance for patients suffering from CCM within the brainstem. The identification of key CCM-relevant mRNAs as putative as well as validated targets for these three prioritized miRNAs strongly indicates their involvement in signaling pathways crucial to CCM pathophysiology. Further functional characterization of these miRNAs in large patient cohorts and animal experimental models would be valuable in determining how they regulate their target gene expression and may be pivotal in considering miRNA antagonism or overexpression as novel therapeutic intervention for improved diagnosis in CCM patients.
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